UP-TO-DATE, RESEARCH BASED INFORMATION ABOUT PSYCHEDELICS. James Hawkins 04/12/2025 James Hawkins 04/12/2025 Exploring practitioners’ perceptions of health behavior changes associated with psychedelic experiences Read More James Hawkins 03/12/2025 James Hawkins 03/12/2025 Psychedelics may enhance emotional closeness and relationship satisfaction when used therapeutically Read More James Hawkins 01/12/2025 James Hawkins 01/12/2025 5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA Read More James Hawkins 01/12/2025 James Hawkins 01/12/2025 Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports Read More James Hawkins 29/11/2025 James Hawkins 29/11/2025 Neurobiological substrates of altered states of consciousness induced by high ventilation breathwork accompanied by music Read More James Hawkins 26/11/2025 James Hawkins 26/11/2025 An evaluation of a psychoeducational harm-reduction focused intervention targeting music festival attendees Read More James Hawkins 26/11/2025 James Hawkins 26/11/2025 Trends in hallucinogen-related emergency department and hospital admissions, 2016 to 2023 Read More Christine Bailey 26/11/2025 Christine Bailey 26/11/2025 Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury Read More Christine Bailey 26/11/2025 Christine Bailey 26/11/2025 Psychedelics in the age of reproducibility: Reflections on aura, set and setting and the medicalization of mystical-type experiences Read More Christine Bailey 18/11/2025 Christine Bailey 18/11/2025 Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults Read More Christine Bailey 18/11/2025 Christine Bailey 18/11/2025 Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations Read More Christine Bailey 12/11/2025 Christine Bailey 12/11/2025 Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy Read More Christine Bailey 11/11/2025 Christine Bailey 11/11/2025 Preclinical study reveals dampened neuronal activity in alcohol-exposed mice Read More James Hawkins 10/11/2025 James Hawkins 10/11/2025 Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials Read More James Hawkins 10/11/2025 James Hawkins 10/11/2025 Dietary changes as a risk factor and remedy for meditation-related challenges Read More James Hawkins 09/11/2025 James Hawkins 09/11/2025 Australian Government announces they will fund psychedelic therapy for veterans with treatment-resistant PTSD or depression Read More James Hawkins 09/11/2025 James Hawkins 09/11/2025 Compass Pathways bring forward the likely commercial launch of their synthetic psilocybin, COMP360, for treatment-resistant depression by 9 to 12 months. Read More James Hawkins 03/11/2025 James Hawkins 03/11/2025 Personal psychedelic experience as a training qualification for facilitators: A thematic analysis of qualitative interviews with psilocybin experts Read More James Hawkins 03/11/2025 James Hawkins 03/11/2025 Beyond prohibition: A public health analysis of naturalistic psychedelic use Read More James Hawkins 03/11/2025 James Hawkins 03/11/2025 Five-year outcomes of psilocybin-assisted therapy for major depressive disorder Read More Older Posts
James Hawkins 04/12/2025 James Hawkins 04/12/2025 Exploring practitioners’ perceptions of health behavior changes associated with psychedelic experiences Read More
James Hawkins 03/12/2025 James Hawkins 03/12/2025 Psychedelics may enhance emotional closeness and relationship satisfaction when used therapeutically Read More
James Hawkins 01/12/2025 James Hawkins 01/12/2025 5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA Read More
James Hawkins 01/12/2025 James Hawkins 01/12/2025 Interactions between psilocybin, LSD, and serotonergic antidepressants: A qualitative analysis of user reports Read More
James Hawkins 29/11/2025 James Hawkins 29/11/2025 Neurobiological substrates of altered states of consciousness induced by high ventilation breathwork accompanied by music Read More
James Hawkins 26/11/2025 James Hawkins 26/11/2025 An evaluation of a psychoeducational harm-reduction focused intervention targeting music festival attendees Read More
James Hawkins 26/11/2025 James Hawkins 26/11/2025 Trends in hallucinogen-related emergency department and hospital admissions, 2016 to 2023 Read More
Christine Bailey 26/11/2025 Christine Bailey 26/11/2025 Psilocybin mitigates chronic behavioral and neurobiological alterations in a rat model of recurrent intimate partner violence-related brain injury Read More
Christine Bailey 26/11/2025 Christine Bailey 26/11/2025 Psychedelics in the age of reproducibility: Reflections on aura, set and setting and the medicalization of mystical-type experiences Read More
Christine Bailey 18/11/2025 Christine Bailey 18/11/2025 Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults Read More
Christine Bailey 18/11/2025 Christine Bailey 18/11/2025 Clinical psychedelic research in adolescents: a scoping review and overview of ethical considerations Read More
Christine Bailey 12/11/2025 Christine Bailey 12/11/2025 Hormonal Influences on Psilocybin Responsivity Across the Female Lifespan: Toward Personalized Psychedelic-Assisted Therapy Read More
Christine Bailey 11/11/2025 Christine Bailey 11/11/2025 Preclinical study reveals dampened neuronal activity in alcohol-exposed mice Read More
James Hawkins 10/11/2025 James Hawkins 10/11/2025 Cognitive and subjective effects of psilocybin microdosing: Results from two double-blind placebo-controlled longitudinal trials Read More
James Hawkins 10/11/2025 James Hawkins 10/11/2025 Dietary changes as a risk factor and remedy for meditation-related challenges Read More
James Hawkins 09/11/2025 James Hawkins 09/11/2025 Australian Government announces they will fund psychedelic therapy for veterans with treatment-resistant PTSD or depression Read More
James Hawkins 09/11/2025 James Hawkins 09/11/2025 Compass Pathways bring forward the likely commercial launch of their synthetic psilocybin, COMP360, for treatment-resistant depression by 9 to 12 months. Read More
James Hawkins 03/11/2025 James Hawkins 03/11/2025 Personal psychedelic experience as a training qualification for facilitators: A thematic analysis of qualitative interviews with psilocybin experts Read More
James Hawkins 03/11/2025 James Hawkins 03/11/2025 Beyond prohibition: A public health analysis of naturalistic psychedelic use Read More
James Hawkins 03/11/2025 James Hawkins 03/11/2025 Five-year outcomes of psilocybin-assisted therapy for major depressive disorder Read More
